Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 7 - Drugs for disorders of the blood or the extracellular fluid
Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065)
11/2005
11/16/2005EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
11/16/2005EP1257550B1 Platelet adp receptor inhibitors
11/16/2005EP1222182B1 Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
11/16/2005EP1220661B1 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid
11/16/2005EP1019493B1 Generation of hematopoietic cells from multipotent neural stem cells
11/16/2005EP0876395B1 Inhibitors of interleukin-1beta converting enzyme
11/16/2005EP0832232B1 Kunitz type plasma kallikrein inhibitors
11/16/2005EP0477295B2 Platelet aggregation inhibitors
11/16/2005CN1697878A Novel peptides having cAMP producing activity
11/16/2005CN1697836A Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists
11/16/2005CN1697655A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
11/16/2005CN1227245C Food product and producing method
11/16/2005CN1227026C Method for using silkworm to express human interleukin 11 to produce medicine
11/16/2005CN1227025C Improved methods for processing activated protein C
11/15/2005US6965049 Zwitterionic lipid compound and uses thereof
11/15/2005US6965018 Antibodies directed to B7-related polypeptide, BSL-2
11/15/2005US6964984 Preventing desensitization of receptors
11/15/2005US6964977 E.g., 5-(((Z)-(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-amino)-1,3-dihydro-2H -benzimidazol-2-one; inhibition or antagonism of protein kinases; treating pain or cancer
11/15/2005US6964973 Nonsteroidal agonists and antagonists
11/15/2005US6964967 Substituted pyrido[2,3-d]pyrimidines and methods for their use
11/15/2005US6964965 Corticotropin releasing factor antagonists
11/15/2005US6964785 Herbal composition for improving anticancer activity, immune response and hematopoiesis of the body, and protecting the body from oxidative damage, and the method of preparing the same
11/15/2005CA2357833C Treatment of pulmonary hypertension using vasopressin antagonist
11/10/2005WO2001009093A8 Benzenamine derivatives as anti-coagulants
11/10/2005US20050250815 e.g. 4-Methoxy-pyrrolidine-1,2-dicarboxylic acid 1-[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide}; anticoagulant, thrombolytic agent; thrombus formation within blood vessels; cardiovascular disease
11/10/2005US20050250771 Substituted indoles and their use as integrin antagonists
11/10/2005US20050250754 Reacting maltol or ethyl maltol with a ferric salt of citric acid, isocitric acid, succinic acid, fumaric acid, maleic acid, malonic acid, aconitic acid, glutaric acid, tartaric acid, gluconic acid, or lactic acid in an aqueous solution containing alkali metal hydroxide or sodium or potassium carbonate
11/10/2005US20050250672 Using antihyperplastic agent; diffusion through capillaries; imaging veins, arteries; side effect reduction; antitumor agents
11/10/2005US20050250183 In vivo incorporation of unnatural amino acids
11/10/2005US20050250150 outer membrane proteins (OMPs) that, alone or in combination, are capable of inducing protective immunity against Lawsonia intracellularis bacteria
11/10/2005US20050249722 Monoclonal antibodies with enhanced ADCC function
11/10/2005US20050249715 Lactoperoxidase; antiinflammatory; thrombocytosis, myeloma, Castleman syndrome, cardiac myxoma, glomerulonephritis, rheumatoid arthritis, sepsis, influenza-virus infectious disease
11/10/2005CA2568436A1 Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor
11/09/2005EP1593682A2 Derivatives of 4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides, process for their preparation and pharmaceutical compositions thereof
11/09/2005EP1593664A1 Nitric esters derivatives of ferulic acid and sulindac with pharmaceutical activity
11/09/2005EP1593390A1 Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
11/09/2005EP1593389A1 Pharmaceutical composition comprising a factor VIIa and a factor XIII
11/09/2005EP1593388A1 Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
11/09/2005EP1593380A2 Use of oligosaccharide for preventing blood clotting in extracorporeal blood circuits
11/09/2005EP1593379A2 Uses of PPAR-gamma agonists in neutrophil-induced diseases
11/09/2005EP1592416A1 Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
11/09/2005EP1405083B1 Natural ligand of gpcr chemr23 and uses thereof
11/09/2005EP1368025B1 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor
11/09/2005EP1292673B1 Thrombomodulin analogs for pharmaceutical use
11/09/2005EP1287142B1 Nucleic acid molecule comprising a nucleic acid sequence coding for an sdf-1 gamma chemokine, a neuropeptide precursor or at least one neuropeptide
11/09/2005EP1278729B1 Benzosuberonylpiperidine compounds as analgesics
11/09/2005EP1214325B1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
11/09/2005EP1212421B1 Gas1 polypeptides
11/09/2005EP1189605B1 High molecular weight primary aliphatic alcohols obtained from beeswax and pharmaceutical use thereof
11/09/2005EP1163236B1 Aromatic heterocyclic compounds as anti-inflammatory agents
11/09/2005EP1095016B1 Sulfur substituted sulfonylaminocarboxylic acid n-arylamides, their preparation, their use and pharmaceutical preparations comprising them
11/09/2005EP0792162B1 Use of antibodies to block the effects of gram-positive bacteria and mycobacteria
11/09/2005CN1694900A EE3-protein family and corresponding DNA sequences
11/09/2005CN1694864A N-bridged selective androgen receptor modulators and methods of use thereof
11/09/2005CN1694719A Casein derived peptides and uses thereof in therapy
11/09/2005CN1226292C Diazesuberane derivant or its salt
11/08/2005US6963011 Central nervous system disorders; psychological disorders
11/08/2005US6962996 Inhibitors of p38
11/08/2005US6962993 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/08/2005US6962942 Azacycloalkanone serine protease inhibitors
11/08/2005US6962939 Condensed indoline derivatives and their use as 5HT, in particular 5HT2C, receptor ligands
11/08/2005US6962937 Imidazolidine derivatives, their preparation and their use
11/08/2005US6962936 Treating diseases such as cancer, inflammatory disorders, restenosis,
11/08/2005US6962933 cerebral hemorrhage/infarction, head trauma, spinal cord injury, brain edema, multiple sclerosis, Alzheimer's/Parkinson's disease, amyotrophic lateral sclerosis, diabetes, osteoporosis, Creutzfeldt-Jakob disease or virus infections
11/08/2005US6962918 Hexahydropyrazino[1'2';1,6]pyrido[3,4-b]indole-1,4-diones for the treatment of cardiovascular disorders and erectile dysfunction
11/08/2005US6962915 Antiinflammatory agents
11/08/2005US6962905 Pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
11/08/2005US6962903 Modified annexin proteins and methods for preventing thrombosis
11/08/2005US6962801 Protein for blocking platelet adhesion
11/08/2005CA2157288C Methods and compositions for inhibition of angiogenesis
11/05/2005CA2506218A1 Use of plasma proteins concentrates containing vwf with a high proportion of high molecular weight multimers
11/03/2005WO2005103238A1 Defibrase modified by polyethylene glycol
11/03/2005WO2005103089A1 Fish-origin chondroitin sulfate/dermatan sulfate hybrid chain
11/03/2005WO2005103012A1 Hydrazino-substituted heterocyclic nitrile compounds and use thereof
11/03/2005WO2005102321A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis
11/03/2005WO2005102314A1 The use of butylphthalide homologues in preparing the drug of preventing and treating cerebral ischemic
11/03/2005US20050245736 Low molecular weight oversulfated polysaccharide
11/03/2005US20050245609 Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
11/03/2005US20050245592 2-Iminopyrrolidine derivatives
11/03/2005US20050245584 Peroxisome proliferator activated receptor agonists
11/03/2005US20050245575 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists
11/03/2005US20050245565 Diamine derivatives
11/03/2005US20050245545 administering a xanthine derivative such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine
11/03/2005US20050245537 Use of compounds having ccr antagonism
11/03/2005US20050245488 Pharmaceutically active compounds and methods of use thereof
11/03/2005US20050244896 Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
11/03/2005US20050244888 Antibodies to human chemokine beta-9
11/03/2005US20050244812 Kits and methods for detection of apoptotic cells
11/03/2005US20050244514 Flavone and adenosine from Ixeris Sonchifolia Hance is more stable in the lyophilized powder form than in liquid form for injection so that it is easy to control the quality of the product so as to make the medicament safe and effective
11/03/2005US20050244508 Anti-spasmodic comprising xenon
11/03/2005US20050244409 Erythropoietin receptor antibodies
11/03/2005US20050244405 Antagonist for endothelial growth agents for treatment of edema and for kidney dialysis
11/03/2005US20050244382 Compositions including ammonia oxidizing bacteria and methods of using same
11/03/2005US20050244372 Interleukin-3 (IL-3) multiple mutation polypeptides
11/03/2005CA2561006A1 Clopidogrel salt and polymorphic forms thereof
11/02/2005EP1591529A2 Human CLTA-8 and uses of CTLA-8-related proteins
11/02/2005EP1591451A1 Peptide conjugate
11/02/2005EP1591443A1 Pyrazole derivative
11/02/2005EP1591135A1 Drug/drug delivery systems for the prevention and treatment of vascular disease
11/02/2005EP1590371A2 Immunoglobulin
1 ... 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 ... 671